Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update (Businesswire) - Mar 14, 2024 - "The KZR-261 trial is currently enrolling Cohort 9 (80 mg/m2). Previously, Cohort 1 (1.8 mg/m2) through Cohort 8 (60 mg/m2) enrolled a total of 35 patients and completed rapid dose escalation without significant safety concerns."
Trial status • Solid Tumor
|